Evidence map›Paper›PMID 32904235›Full record

ArticleHeliyon2020

Durgesh Kumar, Mahendra Kumar Meena, Kamlesh Kumari, Rajan Patel, Abhilash Jayaraj, Prashant Singh

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Durgesh KumarDepartment of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New Delhi, India.
Mahendra Kumar MeenaDepartment of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New Delhi, India.
Kamlesh KumariDeparment of Zoology, Deen Dayal Upadhyaya College, University of Delhi, New Delhi, India.
Rajan PatelCIRBS, Jamia Millia Islamia, New Delhi, India.
Abhilash JayarajSCFBio, Indian Institute of Technology, New Delhi, India.
Prashant SinghDepartment of Chemistry, Atma Ram Sanatan Dharma College, University of Delhi, New Delhi, India.
University of Delhi · INIndian Institute of Technology Delhi · INJamia Millia Islamia · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Literature reported that nsp3 of CHIKV is an important target for the designing of drug as it involves in the replication, survival etc. Herein, about eighteen million molecules available in the ZINC database are filtered against nsp3 using RASPD. Top five hit drug molecules were then taken from the total screened molecules (6988) from ZINC database. Then, a one pot-three components reaction is designed to get the pyrazolophthalazine and its formation was studied using DFT method. Authors created a library of 200 compounds using the product obtained in the reaction and filtered against nsp3 of CHIKV based on docking using iGEMDOCK, a computational tool. Authors have studied the best molecules after applying the the Lipinski's rule of five and bioactive score. Further, the authors took the best compound i.e. CMPD178 and performed the MD simulations and tdMD simulations with nsp3 protease using AMBER18. MD trajectories were studied to collect the information about the nsp3 of CHIKV with and without screened compound and then, MM-GBSA calculations were performed to calculate change in binding free energies for the formation of complex. The aim of the work is to find the potential candidate as promising inhibitor against nsp3 of CHIKV.

Indexed as

DFT studyDockingMD simulationsMulticomponent reactions (MCRs)nsp3 of CHIKVPharmaceutical chemistryTheoretical chemistry

Identifiers

PMID32904235
PMCPMC7452467
OpenAlexW3080660112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.